JP2007506748A5 - - Google Patents

Download PDF

Info

Publication number: JP2007506748A5
Authority: JP; Japan
Prior art keywords: pharmaceutical composition; composition according; methyl; methoxy; dihydroisoquinoline
Prior art date: 2004-09-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP2006528110A

Other languages

English (en)

Japanese (ja)

Other versions

JP4719152B2 (ja

JP2007506748A (ja

Filing date

2004-09-22

Publication date

2007-08-02

2004-09-22 Application filed filed Critical

2004-09-22 Priority claimed from PCT/US2004/030944 external-priority patent/WO2005030727A1/en

2007-03-22 Publication of JP2007506748A publication Critical patent/JP2007506748A/ja

2007-08-02 Publication of JP2007506748A5 publication Critical patent/JP2007506748A5/ja

2011-07-06 Application granted granted Critical

2011-07-06 Publication of JP4719152B2 publication Critical patent/JP4719152B2/ja

2024-09-22 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

239000008194 pharmaceutical composition Substances 0.000 claims 18
206010003119 arrhythmia Diseases 0.000 claims 7
150000001875 compounds Chemical class 0.000 claims 7
230000005764 inhibitory process Effects 0.000 claims 4
206010003658 Atrial Fibrillation Diseases 0.000 claims 3
206010003130 Arrhythmia supraventricular Diseases 0.000 claims 2
206010003662 Atrial flutter Diseases 0.000 claims 2
229940127291 Calcium channel antagonist Drugs 0.000 claims 2
208000005189 Embolism Diseases 0.000 claims 2
241000124008 Mammalia Species 0.000 claims 2
208000003734 Supraventricular Tachycardia Diseases 0.000 claims 2
208000001871 Tachycardia Diseases 0.000 claims 2
239000005557 antagonist Substances 0.000 claims 2
239000000480 calcium channel blocker Substances 0.000 claims 2
239000003937 drug carrier Substances 0.000 claims 2
239000002464 receptor antagonist Substances 0.000 claims 2
229940044551 receptor antagonist Drugs 0.000 claims 2
WNSFBSVZSFGWKG-UHFFFAOYSA-N 2-cyclopropyl-6-methoxy-4-phenyl-3-(1,3-thiazol-2-yl)isoquinolin-1-one Chemical compound C=1C(OC)=CC=C(C(N(C2CC2)C=2C=3SC=CN=3)=O)C=1C=2C1=CC=CC=C1 WNSFBSVZSFGWKG-UHFFFAOYSA-N 0.000 claims 1
QPSHMPFUHZJDOG-UHFFFAOYSA-N 4-(3-fluorophenyl)-6-methoxy-2-methyl-3-(pyrrolidine-1-carbonyl)isoquinolin-1-one Chemical compound C=1C(OC)=CC=C(C(N(C)C=2C(=O)N3CCCC3)=O)C=1C=2C1=CC=CC(F)=C1 QPSHMPFUHZJDOG-UHFFFAOYSA-N 0.000 claims 1
BPWTXMARXPIAPN-UHFFFAOYSA-N 4-(3-fluorophenyl)-6-methoxy-n,n,2-trimethyl-1-oxoisoquinoline-3-carboxamide Chemical compound C=1C(OC)=CC=C(C(N(C)C=2C(=O)N(C)C)=O)C=1C=2C1=CC=CC(F)=C1 BPWTXMARXPIAPN-UHFFFAOYSA-N 0.000 claims 1
229940127239 5 Hydroxytryptamine receptor antagonist Drugs 0.000 claims 1
HQHWFQBVHGZPDU-UHFFFAOYSA-N 6-methoxy-2-methyl-4-phenyl-3-pyridin-2-ylisoquinolin-1-one Chemical compound C=1C(OC)=CC=C(C(N(C)C=2C=3N=CC=CC=3)=O)C=1C=2C1=CC=CC=C1 HQHWFQBVHGZPDU-UHFFFAOYSA-N 0.000 claims 1
LVYBSQBIEGOECD-UHFFFAOYSA-N 7-methoxy-2-methyl-1-oxo-4-phenylisoquinoline-3-carboxylic acid Chemical compound OC(=O)C=1N(C)C(=O)C2=CC(OC)=CC=C2C=1C1=CC=CC=C1 LVYBSQBIEGOECD-UHFFFAOYSA-N 0.000 claims 1
239000005541 ACE inhibitor Substances 0.000 claims 1
229940123413 Angiotensin II antagonist Drugs 0.000 claims 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 1
239000005552 B01AC04 - Clopidogrel Substances 0.000 claims 1
239000005528 B01AC05 - Ticlopidine Substances 0.000 claims 1
102100035023 Carboxypeptidase B2 Human genes 0.000 claims 1
108090000201 Carboxypeptidase B2 Proteins 0.000 claims 1
206010007559 Cardiac failure congestive Diseases 0.000 claims 1
102000002045 Endothelin Human genes 0.000 claims 1
108050009340 Endothelin Proteins 0.000 claims 1
229940123583 Factor Xa inhibitor Drugs 0.000 claims 1
206010019280 Heart failures Diseases 0.000 claims 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 1
229940127449 Integrin Receptor Antagonists Drugs 0.000 claims 1
102000004016 L-Type Calcium Channels Human genes 0.000 claims 1
108090000420 L-Type Calcium Channels Proteins 0.000 claims 1
108091007262 P2T receptors Proteins 0.000 claims 1
102000003691 T-Type Calcium Channels Human genes 0.000 claims 1
108090000030 T-Type Calcium Channels Proteins 0.000 claims 1
229940122388 Thrombin inhibitor Drugs 0.000 claims 1
102000003938 Thromboxane Receptors Human genes 0.000 claims 1
108090000300 Thromboxane Receptors Proteins 0.000 claims 1
229960001138 acetylsalicylic acid Drugs 0.000 claims 1
239000002333 angiotensin II receptor antagonist Substances 0.000 claims 1
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
239000003416 antiarrhythmic agent Substances 0.000 claims 1
239000002876 beta blocker Substances 0.000 claims 1
229940097320 beta blocking agent Drugs 0.000 claims 1
230000000903 blocking effect Effects 0.000 claims 1
239000002368 cardiac glycoside Substances 0.000 claims 1
229940097217 cardiac glycoside Drugs 0.000 claims 1
229960003009 clopidogrel Drugs 0.000 claims 1
GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 claims 1
ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
-1 factor Xa inhibitors Substances 0.000 claims 1
229920000669 heparin Polymers 0.000 claims 1
230000001939 inductive effect Effects 0.000 claims 1
239000003112 inhibitor Substances 0.000 claims 1
239000003055 low molecular weight heparin Substances 0.000 claims 1
229940127215 low-molecular weight heparin Drugs 0.000 claims 1
JHHCUIOLGXFAFI-UHFFFAOYSA-N methyl 4-(3-fluorophenyl)-6-methoxy-2-methyl-1-oxoisoquinoline-3-carboxylate Chemical compound C12=CC(OC)=CC=C2C(=O)N(C)C(C(=O)OC)=C1C1=CC=CC(F)=C1 JHHCUIOLGXFAFI-UHFFFAOYSA-N 0.000 claims 1
CUTKKQAWWOLGDB-UHFFFAOYSA-N methyl 6-methoxy-2-methyl-1-oxo-4-phenylisoquinoline-3-carboxylate Chemical compound C12=CC(OC)=CC=C2C(=O)N(C)C(C(=O)OC)=C1C1=CC=CC=C1 CUTKKQAWWOLGDB-UHFFFAOYSA-N 0.000 claims 1
OAHAJCKNSCXKLU-UHFFFAOYSA-N methyl 7-methoxy-2-methyl-1-oxo-4-phenylisoquinoline-3-carboxylate Chemical compound C12=CC=C(OC)C=C2C(=O)N(C)C(C(=O)OC)=C1C1=CC=CC=C1 OAHAJCKNSCXKLU-UHFFFAOYSA-N 0.000 claims 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
230000002265 prevention Effects 0.000 claims 1
108020003175 receptors Proteins 0.000 claims 1
102000005962 receptors Human genes 0.000 claims 1
230000033764 rhythmic process Effects 0.000 claims 1
150000003839 salts Chemical class 0.000 claims 1
229930002534 steroid glycoside Natural products 0.000 claims 1
150000008143 steroidal glycosides Chemical class 0.000 claims 1
230000006794 tachycardia Effects 0.000 claims 1
239000003868 thrombin inhibitor Substances 0.000 claims 1
229960005001 ticlopidine Drugs 0.000 claims 1
PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 claims 1
PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 claims 1
229960005080 warfarin Drugs 0.000 claims 1

JP2006528110A 2003-09-23 2004-09-22 イソキノリノンカリウムチャネル阻害剤 Expired - Fee Related JP4719152B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US50513803P	2003-09-23	2003-09-23
US60/505,138		2003-09-23
PCT/US2004/030944 WO2005030727A1 (en)	2003-09-23	2004-09-22	Isoquinolinone potassium channel inhibitors

Publications (3)

Publication Number	Publication Date
JP2007506748A JP2007506748A (ja)	2007-03-22
JP2007506748A5 true JP2007506748A5 (2)	2007-08-02
JP4719152B2 JP4719152B2 (ja)	2011-07-06

Family

ID=34392983

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2006528110A Expired - Fee Related JP4719152B2 (ja)	2003-09-23	2004-09-22	イソキノリノンカリウムチャネル阻害剤

Country Status (7)

Country	Link
US (1)	US7781457B2 (2)
EP (1)	EP1667977A4 (2)
JP (1)	JP4719152B2 (2)
CN (1)	CN1856473A (2)
AU (1)	AU2004276267B2 (2)
CA (1)	CA2539541C (2)
WO (1)	WO2005030727A1 (2)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005030729A1 (en) *	2003-09-23	2005-04-07	Merck & Co., Inc.	Isoquinoline potassium channel inhibitors
AU2004289186B2 (en) *	2003-09-23	2010-12-16	Merck Sharp & Dohme Corp.	Isoquinolinone potassium channel inhibitors
EP1667976B1 (en) *	2003-09-23	2010-08-04	Merck Sharp & Dohme Corp.	Isoquinolinone potassium channel inhibitors
US7723352B2 (en) *	2003-09-23	2010-05-25	Merck Sharp & Dohme	Isoquinolinone potassium channel inhibitors
US7569589B2 (en)	2004-07-29	2009-08-04	Merck & Co., Inc.	Potassium channel inhibitors
CN1993347A (zh)	2004-07-29	2007-07-04	默克公司	钾通道抑制剂
CN101277939A (zh)	2005-09-09	2008-10-01	布里斯托尔-迈尔斯斯奎布公司	无环ikur抑制剂
WO2007121453A2 (en) *	2006-04-17	2007-10-25	The Regents Of The University Of California	2-hydroxy-1-oxo 1,2 dihydro isoquinoline chelating agents
BRPI0710946A2 (pt) *	2006-04-27	2012-03-06	Sanofi-Aventis Deutschland Gmbh	inibidores dos canais de Íon task-1 e task-3
DE102006019589A1 (de) *	2006-04-27	2007-10-31	Sanofi-Aventis Deutschland Gmbh	Inhibitoren des TASK-1 und Task-3 Ionenkanals
US8557601B2 (en)	2006-07-10	2013-10-15	The Regents Of The University Of California	Luminescent 1-hydroxy-2-pyridinone chelates of lanthanides
US9623021B2 (en) *	2007-01-22	2017-04-18	Gtx, Inc.	Nuclear receptor binding agents
EA026578B1 (ru)	2007-01-22	2017-04-28	ДЖиТиЭкс, ИНК.	Вещества, связывающие ядерные рецепторы
US9604931B2 (en)	2007-01-22	2017-03-28	Gtx, Inc.	Nuclear receptor binding agents
CA2738313A1 (en) *	2008-09-23	2010-04-08	Georgetown University	Viral and fungal inhibitors
US8563580B2 (en)	2008-09-23	2013-10-22	Georgetown University	Flavivirus inhibitors and methods for their use
WO2011025790A1 (en)	2009-08-24	2011-03-03	Lumiphore, Inc.	Macrocyclic hopo chelators
CA2807886A1 (en) *	2010-09-01	2012-03-08	Gruenenthal Gmbh	Substituted 1-oxo-dihydroisoquinoline-3-carboxamides as kcnq2/3 modulators
CN103864684A (zh) *	2012-12-07	2014-06-18	天津科技大学	一种新颖的3,4-二氢-1(2h)异喹啉类衍生物的合成与抗肿瘤药物的应用
US11453652B2 (en)	2013-03-15	2022-09-27	Lumiphore, Inc.	Di-macrocycles

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69110828T2 (de)	1990-10-16	1995-11-30	Takeda Chemical Industries Ltd	Heterozyklische Aminderivate, deren Herstellung und deren Verwendung.
TW241258B (2)	1992-04-15	1995-02-21	Takeda Pharm Industry Co Ltd
EP0585913B1 (en) *	1992-09-04	1997-12-29	Takeda Chemical Industries, Ltd.	Condensed heterocyclic compounds, their production and use
TW263498B (2) *	1993-11-10	1995-11-21	Takeda Pharm Industry Co Ltd
JPH10298164A (ja) *	1997-02-27	1998-11-10	Tanabe Seiyaku Co Ltd	イソキノリノン誘導体、その製法及びその合成中間体
WO1998038168A1 (en)	1997-02-27	1998-09-03	Tanabe Seiyaku Co., Ltd.	Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors
JP2000072751A (ja) *	1998-08-26	2000-03-07	Tanabe Seiyaku Co Ltd	イソキノリノン誘導体
US6444685B1 (en) *	2000-07-17	2002-09-03	Wyeth	N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists
AU2002212969B2 (en) *	2000-09-20	2006-07-06	Merck Sharp & Dohme Corp.	Isoquinolinone potassium channel inhibitors
SK10802003A3 (sk) *	2001-02-02	2004-05-04	Takeda Chemical Industries, Ltd.	Kondenzovaná heterocyklická zlúčenina, jej použitie a jej farmaceutický prípravok
WO2003068750A1 (en) *	2002-02-13	2003-08-21	Takeda Chemical Industries, Ltd.	Jnk inhibitor
WO2005030729A1 (en) *	2003-09-23	2005-04-07	Merck & Co., Inc.	Isoquinoline potassium channel inhibitors
US7723352B2 (en) *	2003-09-23	2010-05-25	Merck Sharp & Dohme	Isoquinolinone potassium channel inhibitors
EP1667976B1 (en) *	2003-09-23	2010-08-04	Merck Sharp & Dohme Corp.	Isoquinolinone potassium channel inhibitors
AU2004289186B2 (en) *	2003-09-23	2010-12-16	Merck Sharp & Dohme Corp.	Isoquinolinone potassium channel inhibitors

2004
- 2004-09-22 JP JP2006528110A patent/JP4719152B2/ja not_active Expired - Fee Related
- 2004-09-22 WO PCT/US2004/030944 patent/WO2005030727A1/en not_active Ceased
- 2004-09-22 US US10/572,343 patent/US7781457B2/en not_active Expired - Fee Related
- 2004-09-22 CN CNA2004800273785A patent/CN1856473A/zh active Pending
- 2004-09-22 AU AU2004276267A patent/AU2004276267B2/en not_active Ceased
- 2004-09-22 EP EP04788883A patent/EP1667977A4/en not_active Withdrawn
- 2004-09-22 CA CA2539541A patent/CA2539541C/en not_active Expired - Fee Related

Publication	Publication Date	Title
JP2007506748A5 (2)	2007-08-02
JP2007516218A5 (2)	2007-08-02
JP2007506742A5 (2)	2007-08-02
WO2008073392A3 (en)	2008-12-18	Compositions and methods for cardiac tissue protection and regeneration
JP2007511487A5 (2)	2008-02-07
CN104147010A (zh)	2014-11-19	治疗心房颤动的方法
JP2004533464A5 (2)	2006-01-05
CA2539541A1 (en)	2005-04-07	Isoquinolinone potassium channel inhibitors
HK1052170A1 (zh)	2003-09-05	新型化合物抑制因子xa活度
Fiala et al.	2008	Termination of long‐lasting persistent versus short‐lasting persistent and paroxysmal atrial fibrillation by ablation
NO20070148L (no)	2007-01-09	Nye oksabispidinforbindelser og deres anvendelse ved behandling av forstyrrelser i hjerterytmen
JP2007527904A5 (2)	2008-02-07
JP2011068661A (ja)	2011-04-07	洞房結節Ｉｆ電流阻害剤およびカルシウム阻害剤の新規な組み合わせならびにそれを含む医薬組成物
ES2296964T3 (es)	2008-05-01	Compuestos a base de nitrato organico para el tratamiento de ateroesclerosis y enfermedades vasculares.
WO2009114716A3 (en)	2010-03-11	Use of epicatechin and derivatives and salts thereof for cardiac protection of ischemic myocardium and to ameliorate adverse cardiac remodeling
NO20070147L (no)	2007-01-09	Nye oksabispidinforbindelser og deres anvendelse ved behandling av forstyrrelser i hjerterytmen
RU2004136583A (ru)	2005-09-10	Применение валсартана или его метаболита для ингибирования агрегации тромбоцитов
MY138896A (en)	2009-08-28	Derivatives of 3-(guanidinocarbonyl) heterocycle, methods of preparation and intermediates thereof, their use as medicaments, and pharmaceutical compositions therefrom
JP2007527903A5 (2)	2008-02-07
JP6336484B2 (ja)	2018-06-06	遅延ナトリウム電流遮断薬および洞房結節ｉｆ電流阻害薬の組合せ、ならびに該組合せを含む医薬組成物
Pinter et al.	2010	New approaches to atrial fibrillation management: treat the patient, not the ECG
JP2008516952A5 (2)	2008-10-30
CA2590224A1 (en)	2006-06-22	Method for reduction, stabilization and prevention of rupture of lipid rich plaque
JP2008524228A5 (2)	2009-02-05
MY176510A (en)	2020-08-12	2-(butyl-1-sulfonylamino)-n-[1(r)-(6-methoxypyridin-3-yl)propyl]benz-amide, its use as a medicament, and pharmaceutical preparations comprising it